GMED - Globus Medical, Inc.
After hours:
| Previous Close | 54.13 |
| Open | 54.49 |
| Bid | 0.00 x 900 |
| Ask | 64.00 x 900 |
| Day's Range | 54.05 - 55.42 |
| 52 Week Range | 50.92 - 80.04 |
| Volume | |
| Avg. Volume | 1,425,646 |
| Market Cap | 5.629B |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | 26.83 |
| EPS (TTM) | 2.05 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 67.20 |
ZacksHere's Why You Should Retain Globus Medical (GMED) Stock Now
Investors continue to be optimistic about Globus Medical (GMED) based on the strong performances across geographies and the pending NuVasive acquisition.
Simply Wall St.Is Globus Medical, Inc. (NYSE:GMED) Potentially Undervalued?
Globus Medical, Inc. ( NYSE:GMED ), is not the largest company out there, but it received a lot of attention from a...
ZacksGlobus Medical's (GMED) REFLECT Correction System Gets FDA Nod
Globus Medical's (GMED) REFLECT is intended to treat young children with progressive scoliosis, while preserving motion, stability and future modulated growth.
GlobeNewswireGlobus Medical Announces FDA Approval for its Non-Fusion Scoliosis Correction System, the Latest Advancement for Young Patients with Idiopathic Scoliosis
REFLECT™ is approved through the FDA’s Humanitarian Device Exemption pathwayAUDUBON, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the REFLECT™ Scoliosis Correction System has been granted approval from the US Food and Drug Administration, as the company’s first humanitarian device. REFLECT™ is designed to correct progressive scoliosis in young patients while preserving motion, maintaining stability, and allo
ZacksGlobus Medical (GMED) Q1 Earnings Beat, Operating Margin Dips
The significant year-over-year surge in Globus Medical's (GMED) Enabling Technologies sales is driven by ongoing demand for the company's robotics and imaging system technologies.
- Thomson Reuters StreetEvents
Q1 2023 Globus Medical Inc Earnings Call
Q1 2023 Globus Medical Inc Earnings Call
Motley FoolGlobus Medical (GMED) Q1 2023 Earnings Call Transcript
Joining today's call from Globus Medical will be Dan Scavilla, president and chief executive officer; and Keith Pfeil, chief financial officer. This review is being made available via webcast, accessible through the Investor Relations section of the Globus Medical website at www.globusmedical.com.
ZacksGlobus Medical (GMED) Surpasses Q1 Earnings and Revenue Estimates
Globus Medical (GMED) delivered earnings and revenue surprises of 3.92% and 8.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Globus Medical Reports First Quarter 2023 Results
AUDUBON, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2023. Worldwide net sales were $276.7 million, an increase of 20.0%, or 21.0% on a constant currency basisGAAP net income for the quarter was $49.1 millionGAAP diluted earnings per share (“EPS”) was $0.48 and non-GAAP diluted EPS was $0.53Non-GAAP adjusted EBITDA was $85.1 million, or 30.8% of net sale
ZacksGlaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
Glaukos (GKOS) delivered earnings and revenue surprises of 3.28% and 10.38%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Globus Medical Shareholders Approve Share Issuance for Merger with NuVasive
AUDUBON, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that at the special meeting of shareholders held earlier today its shareholders voted to approve the issuance of shares of Globus Medical Class A common stock in connection with the proposed merger with NuVasive (NASDAQ: NUVA). As previously announced, under the terms of the merger agreement, Globus Medical will issue 0.75 of a share of Globus Medical Cl
- Simply Wall St.
Globus Medical's (NYSE:GMED) investors will be pleased with their 22% return over the last three years
It hasn't been the best quarter for Globus Medical, Inc. ( NYSE:GMED ) shareholders, since the share price has fallen...
- GlobeNewswire
Globus Medical Schedules First Quarter Earnings Release and Conference Call
AUDUBON, Pa., April 19, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the first quarter ended March 31, 2023 after the market close on Thursday, May 4, 2023. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m
- Zacks
Globus' (GMED) NUVA Buyout Seems Strategic, Cost Woe Stays
Globus Medical (GMED) and NuVasive (NUVA) are currently planning to combine in an all-stock transaction to create a global musculoskeletal company.
Motley FoolInflation, TikTok, and Other Hot Stories Investors Are Talking About
In this Motley Fool Money podcast, Motley Fool senior analysts Emily Flippen and Ron Gross join host Chris Hill to discuss: Fear of a recession vs. fear of banking contagion. Whether social media giants like Meta Platforms and Snap stand to benefit from the drama around TikTok.
- Zacks
Globus Medical (GMED) to Gain From NUVA Deal Amid Rising Costs
The NuVasive acquisition aims to outpace market growth by combining Globus Medical's (GMED) engineering and NuVasive's relations, education and training.
- Zacks
NuVasive (NUVA), GMED Merger Aids, Macro Woes Mar Growth
According to NuVasive (NUVA), the combined company is set to have an advanced commercial scale and portfolio of clinically proven solutions.
- Simply Wall St.
Is Now The Time To Put Globus Medical (NYSE:GMED) On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
ZacksBear of the Day: NuVasive (NUVA)
Softer results for spinal surgery innovator plus questionable merger have dropped estimates and shares
- Simply Wall St.
Globus Medical Full Year 2022 Earnings: EPS Misses Expectations
Globus Medical ( NYSE:GMED ) Full Year 2022 Results Key Financial Results Revenue: US$1.02b (up 6.8% from FY 2021). Net...
ZacksGlobus Medical (GMED) Q4 Earnings Beat, Operating Margin Rises
Globus Medical (GMED) reports strong fourth-quarter sales growth amid currency headwinds and lingering COVID-19 impacts.
- Motley Fool
Globus Medical (GMED) Q4 2022 Earnings Call Transcript
Thank you for standing by, and welcome to Globus medical's fourth quarter and full year 2022 earnings conference call. Joining today's call from Globus Medical will be Dan Scavilla, president and CEO; and Keith Pfeil, chief financial officer.
ZacksGlobus Medical (GMED) Tops Q4 Earnings Estimates
Globus Medical (GMED) delivered earnings and revenue surprises of 7.27% and 0.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Globus Medical Reports Fourth Quarter and Full Year 2022 Results
AUDUBON, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2022. Fourth Quarter 2022: Worldwide net sales were $274.5 million, an increase of 9.8%, or 11.7% on a constant currency basisGAAP net income for the quarter was $50.1 millionGAAP diluted earnings per share (“EPS”) was $0.49 and non-GAAP diluted EPS was $0.59Non-GAAP adjusted EBITDA
ZacksShockwave Medical (SWAV) Q4 Earnings and Revenues Surpass Estimates
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 274.75% and 1.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
